Hospital
Covenant Hospital Hobbs
Covenant Hospital Hobbs was paid $10.10M by Medicaid between Sep 2021 and Dec 2024, across 158 billing codes. Its largest line is 99284, emergency room visit (serious) — 17% of everything it billed.
33Billing provider infoCOVENANT HOSPITAL HOBBS
HOBBS, NM 88240
HOBBS, NM 88240
33aNPI1215534466assigned 10/01/2020
33bProvider typeGeneral Acute Care Hospital
28Total paid$10.10M
24GClaims174,935
24DCodes billed158
24AFirst – last monthSep 2021 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in New Mexico
Rank by total paid#19 of 24
Median peer was paid$20.13M
This provider vs. median0.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official ANDERSON, DONALD controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2021 | 4,318 | $192K | |
| 2022 | 51,125 | $2.51M | |
| 2023 | 60,946 | $3.49M | |
| 2024incomplete | 58,546 | $3.90M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 17% | 7,997 | 7,557 | $1.74M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 17% | 10,725 | 10,287 | $1.69M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 14% | 5,269 | 4,934 | $1.41M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 5.2% | 1,174 | 1,143 | $529K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.8% | 1,798 | 1,727 | $382K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 3.0% | 1,002 | 974 | $305K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.7% | 4,076 | 3,737 | $276K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 2.2% | 2,464 | 2,227 | $219K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.1% | 5,427 | 5,063 | $213K |
| 71045 | Radiologic examination, chest; single view | 1.9% | 4,104 | 3,799 | $197K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 1.9% | 6,605 | 6,354 | $196K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.8% | 4,121 | 3,625 | $184K |
146 more codes
| 80053 | Comprehensive metabolic panel | 1.8% | 11,467 | $181K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.5% | 1,406 | $148K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.2% | 12,444 | $119K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 734 | $101K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,135 | $97K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,642 | $93K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,624 | $92K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 310 | $87K |
| G0378 | Hospital observation service, per hour | <1% | 278 | $85K |
| 84484 | <1% | 3,221 | $85K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 7,468 | $82K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,332 | $82K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 2,049 | $63K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,927 | $59K |
| 87807 | <1% | 917 | $54K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 511 | $51K |
| 83690 | <1% | 2,650 | $48K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 570 | $45K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 698 | $43K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,271 | $41K |
| 73610 | <1% | 385 | $39K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,180 | $35K |
| 83880 | <1% | 1,328 | $33K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,933 | $32K |
| 73562 | <1% | 356 | $30K | |
| 84702 | <1% | 913 | $30K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,154 | $29K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 536 | $29K |
| 84703 | <1% | 1,311 | $28K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 287 | $27K |
| J3490 | Unclassified drugs | <1% | 164 | $27K |
| 73630 | <1% | 344 | $25K | |
| 81001 | <1% | 4,053 | $24K | |
| 96376 | <1% | 1,200 | $24K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 235 | $23K |
| 83605 | <1% | 1,337 | $23K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,580 | $23K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,082 | $23K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 720 | $22K |
| 73030 | <1% | 275 | $22K | |
| 74018 | <1% | 375 | $22K | |
| 83735 | <1% | 1,240 | $20K | |
| J2704 | Injection, propofol, 10 mg | <1% | 683 | $20K |
| 87040 | <1% | 732 | $18K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,382 | $18K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,847 | $17K |
| 76801 | <1% | 126 | $16K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 880 | $15K |
| 85379 | <1% | 714 | $15K | |
| 76830 | Ultrasound, transvaginal | <1% | 109 | $15K |
| 80061 | Lipid panel | <1% | 813 | $15K |
| 73130 | <1% | 202 | $14K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 85 | $13K |
| 86850 | <1% | 681 | $13K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 2,984 | $13K |
| 73110 | <1% | 173 | $13K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 798 | $12K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 102 | $12K |
| 81003 | <1% | 2,337 | $11K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,133 | $10K |
| 86900 | <1% | 910 | $10K | |
| 86901 | <1% | 909 | $10K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 408 | $8K |
| 87186 | <1% | 447 | $8K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 410 | $8K |
| 86140 | <1% | 482 | $8K | |
| 82077 | <1% | 281 | $7K | |
| 81025 | <1% | 1,333 | $7K | |
| 84439 | <1% | 390 | $7K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 480 | $7K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 697 | $7K |
| 85027 | <1% | 1,219 | $6K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 475 | $6K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 30 | $6K |
| 82150 | <1% | 244 | $6K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 450 | $6K |
| 85610 | <1% | 1,078 | $5K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 345 | $5K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 579 | $5K |
| 76642 | <1% | 41 | $5K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 511 | $5K |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 38 | $5K |
| 82962 | <1% | 1,745 | $5K | |
| 85730 | <1% | 384 | $5K | |
| 72100 | <1% | 57 | $4K | |
| 90715 | <1% | 113 | $4K | |
| 93971 | <1% | 36 | $4K | |
| 82550 | <1% | 318 | $4K | |
| 80143 | <1% | 133 | $4K | |
| 80179 | <1% | 129 | $4K | |
| 82803 | <1% | 68 | $4K | |
| 82553 | <1% | 223 | $4K | |
| 70486 | <1% | 14 | $3K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 256 | $3K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 236 | $3K |
| 86803 | <1% | 280 | $3K | |
| 73590 | <1% | 33 | $3K | |
| 73090 | <1% | 32 | $2K | |
| 73502 | <1% | 57 | $2K | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 122 | $2K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 248 | $2K |
| 87088 | <1% | 103 | $2K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 15 | $2K |
| 87340 | <1% | 268 | $2K | |
| 90714 | <1% | 58 | $2K | |
| 86780 | <1% | 187 | $2K | |
| 87420 | <1% | 161 | $1K | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 147 | $1K |
| 73140 | <1% | 18 | $1K | |
| 86762 | <1% | 164 | $1K | |
| 12001 | <1% | 12 | $1K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 105 | $1K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 24 | $1K |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 123 | $1K |
| 82950 | <1% | 133 | $1K | |
| 87081 | <1% | 134 | $1K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 173 | $1K |
| 76641 | <1% | 12 | $1K | |
| 84100 | <1% | 93 | $1K | |
| 73564 | <1% | 13 | $1K | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 374 | $998.35 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 28 | $951.98 |
| J0137 | Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg | <1% | 57 | $756.52 |
| 87070 | <1% | 36 | $708.34 | |
| 86592 | <1% | 205 | $651.66 | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 31 | $625.52 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 47 | $560.94 |
| 81005 | <1% | 65 | $530.71 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 36 | $530.18 |
| A9270 | Non-covered item or service | <1% | 565 | $458.92 |
| J1836 | Injection, metronidazole, 10 mg | <1% | 15 | $366.67 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 27 | $341.38 |
| J7999 | Compounded drug, not otherwise classified | <1% | 21 | $294.55 |
| J7510 | Prednisolone oral, per 5 mg | <1% | 151 | $261.68 |
| 96367 | <1% | 18 | $258.91 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 16 | $249.41 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 42 | $225.38 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 37 | $214.60 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 51 | $178.62 |
| J1815 | Injection, insulin, per 5 units | <1% | 121 | $176.47 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 13 | $167.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 21 | $142.77 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 12 | $137.74 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 20 | $107.59 |
| 82607 | <1% | 12 | $78.20 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 1,545 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialANDERSON, DONALD (ASSISTANT SECRETARY FOR ENROLLMENT)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.